Positive results of a cost effectiveness study presented at the XXXIst International Workshop on Helicobacter & Microbiota in Inflammation and Cancer on September 14, 2018 in Kaunas (Lithuania). Data show that in patients with uninvestigated dyspepsia, the “Test and Treat” strategy incorporating Urea Breath Test as implemented in Spain is as effective and more cost effective than the Endoscopy-only strategy with regard to dyspepsia relief and gastric cancer prevention.

Press release

During 4 days, International & Business Team managed our booth at Arab Health, the largest gathering of healthcare/Pharma in the MEA region. The 2018 edition included more than 4,200 exhibiting companies and more than 10,000 attendees from 150+ countries (mainly from MEA region). Our partner in Emirates & Saudi Arabia, Gulf Drug, was gold sponsor of the event, and we received very good feedback of their expertise in the Region.

Mayoly booth was based on French Pavillon even if our neighbour were from Belgium ! Was highlighted the Topicrem products, the HP Franchise with 1 KIBION DYNAMIC & 1 HELIPROBE, the IBS family and the Probiotics franchise, in addition to all others products of the Mayoly.

Supporting for a part the Contract Manufacturing activities (and Calcidose received  a very good feedback !), the main objective was to (1) to find new products, and (2) to find new partners for new countries.

After around 200 business cards exchanges, and 4 exhausting days, the conclusion is very positive. We met a lot of Pharmaceutical companies & distributors from Emirates, Saudi Arabia, Iran, Irak, Syria, Jordan, Kuwait, Oman, Bahrain, Yemen, for Middle East, or Kenya and Sudan for Africa for example.

Products presentation, company introduction have been done already, and the follow-up of this event is now crucial, to be able to valuate these 4 days, by new business openings. Our key products have been plebiscited, but some others products, not targeted as priority, may have some potential based on the number of interests received (Colchicine, Calcidose, Cholurso, and the suppository range).

We hope now that business cases arriving in the coming months will be approved to increase our business level in this part of the world, where market growth is very interesting.

We already took an appointment for next year!

Discover the first institutional Motion Design of our company !

In 2min30, this graphic animation presents in a synthetic way all the activities of Mayoly Spindler.

Our Laboratoires Galéniques Vernin (LGV) website has been changed : www.lgvfrance.com !

As a softgel capsules expert since the ealy 1990s, LGV is the production unit of Mayoly Spindler.

We are pleased to inform you that Kibion, entity of Laboratories Mayoly Spindler, received the SWECARE Award on 26 April 2017 for its outstanding export performance.

The jury that awarded the prize, said :

“By adopting a clear business strategy, Kibion has increased its sales in 2016 by 39% compared to 2015”.

The purpose of the award is to encourage and reward Swedish companies which have an innovative and creative international policy in the field of health.

On 26 April 2017 in Stockholm at the annual Swecare congress, Petter Bäckgren received the prize from Agneta Karlsson, State Secretary for Public Health and Gabriel Wikström Sport Minister.

Swecare is an organization where the academic community and the public and private sectors work together to promote internationally the Swedish healthcare system and the companies involved.

Read the Press Release

As every year, our laboratory visited EuroPlx, a business development and licensing Exhibition held in Cascais, Portugal, welcoming about 244 companies represented in 44 countries around the world.

https://www.europlx.com/euroPLX-66

Mayoly Spindler expands its management team to support the implementation of an ambitious development cycle

As the French and international world of healthcare faces major changes, Mayoly Spindler, committed to a trajectory of growth, is expanding its management team and consolidating its organization to ensure the soundness and vitality of the components of its success.

“In the five years to come, more than half of our growth will come from new products or new countries and our ability to prepare and carry out these launches is crucial. For our pharmaceutical business, France represents—and will continue to represent—around half of our sales revenue. Under increasing strains and facing ongoing redefinition, it is essential that we have a strong framework in France, capable of sustaining its commercial competitiveness, building the future by fostering the development of new professions and know-how, and contributing to Mayoly Spindler’s strategic thinking”, reports Stéphane THIROLOIX, CEO of MAYOLY SPINDLER.

Press Release

During their meeting on 6 December 2016, the Leem Board of Directors (Les Entreprises du Médicament) [The pharmaceutical Industry] appointed a new director, Stéphane Thiroloix, General Manager of the Laboratoires Mayoly Spindler, a “Medium-sized French Laboratory”.

Stéphane Thiroloix is a graduate of the HEC (École des Hautes Études Commerciales [Paris Business School]).
He began his career in 1987 at Roussel Uclaf (now Sanofi), where, for eleven years, he held roles in Marketing/Sales and General Management in South Africa, Mexico, Australia and France.

In 1998, he joined SmithKline Beecham (now GlaxoSmithKline), where he was appointed Vice-President and Director of French Operations, and then Vice-President for Europe in Business Development and Marketing Alliances.

From 2002 to 2007, Stéphane Thiroloix was Vice-President of French Operations and then became Vice-President for Europe and General Manager for France at Bristol-Myers Squibb.

In 2007, he joined the Ispen company’s executive committee as Executive Vice-President of Corporate Development and held this position until 2011, the year he became President of Smith & Nephew’s Advanced Surgical Devices (ASD) Division for Europe, Canada, Japan and Australia.

In 2014, Stéphane Thiroloix became General Manager of Laboratoires Mayoly Spindler.

Mayoly Bela officially opened in November 17th 2016.

Belarus is a major market in CIS region where Mayoly Spindler commercializes its products since 15 years.

Contact Business center “Victoria Olimp” Bulvard Pabediteliy, 103 Office # 1314 Minsk

There are approximately 100,000 patients in the U.S. with EPI caused by CP according to the National Pancreas Foundation and more than 30,000 patients with EPI caused by cystic fibrosis according to the Cystic Fibrosis Foundation. Patients are currently treated with porcine pancreatic enzyme replacement pills.

BROOKLYN, N.Y., 17 NOV. 2016 (GLOBE NEWSWIRE) ‐‐ AZURRX BIOPHARMA INC. (NASDAQ:AZRX)

(“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today that in partnership with Mayoly Spindler, a European pharmaceutical company, the initiation of a Phase II clinical trial evaluating the safety and efficacy of MS1819-SD in patients with exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP).

The open-label, dose escalation Phase II study is being conducted in two sites in Australia

The Royal Adelaide Hospital and Linear Clinical Research in Perth as well as two sites in New Zealand, P3 Research in Wellington and CCST in Christchurch.  The study is projected to enroll approximately 12 patients with EPI caused by chronic pancreatitis over the next several months.  Dr. Quoc Nam Ngyuen, Associate Professor in the Department of Gastroenterology at the Royal Adelaide Hospital is the principal investigator for the study.

The primary objective of this Phase II study is to investigate the safety of escalating doses of MS1819-SD in patients with chronic pancreatitis. The secondary objective is to investigate the efficacy of MS1819-SD in these patients by analysis of the coefficient of fat absorption and its change from baseline. Initial study results from the MS1819-SD Phase II study are expected in the first half of 2017.

Read more